世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

世界の子宮頸がんジストニア治療市場 2019-2023年

Global Cervical Dystonia Therapeutics Market 2019-2023

IRTNTR30167

 

出版社 出版年月電子版価格 ページ数
TechNavio
テクナビオ
2018年10月US$2,500
シングルユーザライセンス
114

サマリー

この調査レポートは世界の子宮頸がんジストニア治療市場を分析・予測したTechNavioの市場調査報告書です。

Description

113 pages, November 2018

About this market


With the rise in reimbursement programs for botulinum neurotoxin injections, there is a growing demand for treatment of cervical dystonia. Several reimbursement programs are available to help people access the high-cost botulinum neurotoxin therapy for the treatment of cervical dystonia. These reimbursement programs help patients with or without medical insurance to achieve appropriate reimbursement for their treatment with botulinum toxins. For instance, Allergan, the manufacturer of BOTOX, sponsors a comprehensive reimbursement program called as BOTOX Reimbursement Solutions Program. This program includes a BOTOX Hotline and BOTOX Patient Assistance Program to assist patients who are receiving BOTOX injection treatment. Technavio’s analysts have predicted that the cervical dystonia therapeutics market will register a CAGR of almost 5% by 2023.

Market Overview


Expected approval of late-stage pipeline molecules
The global cervical dystonia therapeutics industry is forecasted to witness a steady growth owing to the expected approval of late-stage molecules in the pipeline for the treatment of cervical dystonia. The cervical dystonia therapeutics market is also expected to benefit from the growing number of molecules being launched for the treatment of the disease.
Availability of alternate therapies
For the treatment of cervical dystonia, botulinum toxins and other therapeutics are used. However, the low rate of success and temporary cure of these therapeutics leads people towards alternative therapies such as DBS surgery, which is a major challenge for the growth of the market.
For the detailed list of factors that will drive and challenge the growth of the cervical dystonia therapeutics market during the 2019-2023 period, view our report.

Competitive Landscape


The market appears to be fragmented and with the presence of several companies including Allergan and Eisai, the competitive environment is quite intense. Factors such as the rising number of reimbursement programs for botulinum neurotoxin injections and the anticipated approval of late-stage pipeline molecules, will provide considerable growth opportunities to cervical dystonia therapeutic vendors. Allergan, Eisai, Ipsen Pharma, Merz Pharma, and US WorldMeds are some of the major companies covered in this report.



目次

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 04: MARKET SIZING
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
- Market segmentation by product
- Comparison by product
- Botulinum toxins - Market size and forecast 2018-2023
- Other therapeutics - Market size and forecast 2018-2023
- Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- Americas - Market size and forecast 2018-2023
- EMEA - Market size and forecast 2018-2023
- APAC - Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
- Overview
- Landscape disruption
- Competitive scenario
PART 13: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Allergan
- Eisai
- Ipsen Pharma
- Merz Pharma
- US WorldMeds
PART 14: APPENDIX
- Research methodology
- List of abbreviations
PART 15: EXPLORE TECHNAVIO

Exhibit 01: Global CNS therapeutics market
Exhibit 02: Segments of global CNS therapeutics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Product - Market share 2018-2023 (%)
Exhibit 18: Comparison by product
Exhibit 19: Botulinum toxins - Market size and forecast 2018-2023 ($ millions)
Exhibit 20: Botulinum toxins - Year-over-year growth 2019-2023 (%)
Exhibit 21: Other therapeutics - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Other Therapeutics - Year-over-year growth 2019-2023 (%)
Exhibit 23: Market opportunity by product
Exhibit 24: Customer landscape
Exhibit 25: Market share by geography 2018-2023 (%)
Exhibit 26: Geographic comparison
Exhibit 27: Americas - Market size and forecast 2018-2023 ($ millions)
Exhibit 28: Americas - Year-over-year growth 2019-2023 (%)
Exhibit 29: Top 3 countries in Americas
Exhibit 30: EMEA - Market size and forecast 2018-2023 ($ millions)
Exhibit 31: EMEA - Year-over-year growth 2019-2023 (%)
Exhibit 32: Top 3 countries in EMEA
Exhibit 33: APAC - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: APAC - Year-over-year growth 2019-2023 (%)
Exhibit 35: Top 3 countries in APAC
Exhibit 36: Key leading countries
Exhibit 37: Market opportunity
Exhibit 38: Impact of drivers and challenges
Exhibit 39: Vendor landscape
Exhibit 40: Landscape disruption
Exhibit 41: Vendors covered
Exhibit 42: Vendor classification
Exhibit 43: Market positioning of vendors
Exhibit 44: ALLERGAN - Vendor overview
Exhibit 45: ALLERGAN - Business segments
Exhibit 46: ALLERGAN - Organizational developments
Exhibit 47: ALLERGAN - Geographic focus
Exhibit 48: ALLERGAN - Segment focus
Exhibit 49: ALLERGAN - Key offerings
Exhibit 50: ALLERGAN - Key customers
Exhibit 51: Eisai - Vendor overview
Exhibit 52: Eisai - Business segments
Exhibit 53: Eisai - Organizational developments
Exhibit 54: Eisai - Geographic focus
Exhibit 55: Eisai - Segment focus
Exhibit 56: Eisai - Key offerings
Exhibit 57: Eisai - Key customers
Exhibit 58: Ipsen Pharma - Vendor overview
Exhibit 59: Ipsen Pharma - Business segments
Exhibit 60: Ipsen Pharma - Organizational developments
Exhibit 61: Ipsen Pharma - Geographic focus
Exhibit 62: Ipsen Pharma - Segment focus
Exhibit 63: Ipsen Pharma - Key offerings
Exhibit 64: Ipsen Pharma - Key customers
Exhibit 65: Merz Pharma - Vendor overview
Exhibit 66: Merz Pharma - Business segments
Exhibit 67: Merz Pharma - Organizational developments
Exhibit 68: Merz Pharma - Geographic focus
Exhibit 69: Merz Pharma - Segment focus
Exhibit 70: Merz Pharma - Key offerings
Exhibit 71: Merz Pharma - Key customers
Exhibit 72: US WorldMeds - Vendor overview
Exhibit 73: US WorldMeds - Organizational developments
Exhibit 74: US WorldMeds - Key offerings
Exhibit 75: US WorldMeds - Key customers



 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る